Busulfan is primarily used as an antineoplastic agent, specifically for the treatment of chronic myeloid leukemia (CML), with a remission rate of 80–90%. It is a cell cycle non-specific alkylating agent that predominantly acts on the G1 and M phases. At low doses, it selectively suppresses granulocyte production in the bone marrow with minimal effect on erythrocytes and lymphocytes; however, at high doses, it also inhibits the production of erythrocytes and lymphocytes. Busulfan is also used in conditioning regimens prior to hematopoietic stem cell transplantation due to its myeloablative properties.